Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell LymphomaManik Uppal, Bhavneet Bhinder, Andrew R Marderstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell TherapyRoni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.Leukemia|November 6, 2022
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphomaAna Alarcon Tomas, Joshua A Fein, Shalev Fried, et al.Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.Nature Communications|October 29, 2023
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencingRyan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran, et al.Pageof 3